Arca
Skip to content
Tools
Tools

Nephrotic syndrome

Drug research and approvals for nephrotic syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 55 studies of nephrotic syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, FDA has 2 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 55
  • Trials authorized in Canada: 1
  • FDA orphan approvals: 2
  • EU medicines: 1

Recruiting now

Newest posted first, of 55 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 16

Phase 3 10

Phase 2 10

Phase 1 or earlier 1

How its trials ended

175 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 33 whose ending is known, 33% met their primary endpoint, 9% missed it and 58% stopped early.

  • Ongoing5934%
  • Completed, result not reported5330%
  • Status unknown3017%
  • Met its primary endpoint116%
  • Stopped: other or unclear116%
  • Missed its primary endpoint32%
  • Stopped: lack of efficacy32%
  • Stopped: enrollment or feasibility32%
  • Stopped: sponsor or business decision21%

Trials authorized in Canada

Newest first; search them all in Canada trials
AuthorizedTrialSponsorStatus
Sep 6, 2023Second line immune suppressive drugs in frequently relapsing childhood nephrotic syndrome: a 3-arm randomized trial comparing cyclophosphamide, tacrolimus &…Cyclophosphamide / Mycophenolate / TacrolimusGovernors of The University of CalgaryPending

FDA orphan designations

Approved first, then open designations, newest first
Sep 25, 2026GazyvaTo reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent…Genentech, Inc.Approved
Apr 13, 2026FilspariTo reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without…Travere Therapeutics, Inc.Approved
Jul 20, 2022Pioglitazone hydrochlorideTreatment of childhood onset idiopathic nephrotic syndrome (defined as steroid dependent or frequently relapsing NS).NephKey Therapeutics, Inc.Designated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
May 26, 2023QaialdoSpironolactoneLipomed GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.